This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

New Clinical Data On AVEO Oncology’s Tivozanib And Ficlatuzumab To Be Presented At The ESMO 2012 Congress

Stock quotes in this article: AVEO

AVEO Oncology (NASDAQ: AVEO) today announced that new clinical data on its lead product candidate tivozanib, partnered with Astellas Pharma Inc. (TSE: 4503), as well as its HGF inhibitory antibody ficlatuzumab will be presented at the European Society of Medical Oncology (ESMO) 2012 Congress in Vienna, Austria, September 28 – October 2, 2012.

“At this year’s ESMO, investigators will present new data on both our lead product candidate tivozanib and our HGF inhibitory antibody ficlatuzumab,” said William Slichenmyer, M.D., Sc.M., chief medical officer, AVEO Oncology. “We believe the additional TIVO-1 analyses underscore the safety profile of tivozanib in RCC while the new ficlatuzumab data demonstrate its targeted inhibition of the HGF ligand. We look forward to sharing these data with the medical oncology community soon.”

The schedule for the tivozanib and ficlatuzumab data presentations at ESMO is as follows:

Date & Time: Saturday, September 29, 2012 at 1:00 p.m. (CEST)
Session: Poster presentation 1
Title: A randomized Phase (Ph) 2 study with exploratory biomarker analysis of ficlatuzumab (F) a humanized hepatocyte growth factor (HGF) inhibitory MAB in combination with gefitinib (G) versus G in Asian patients (PTS) with lung adenocarcinoma (LA)
Abstract Number: 1198P
Room: Hall XL
Presenter: Tony Mok, M.D.
Date & Time: Saturday, September 29, 2012 at 1:00 p.m. (CEST)
Session: Poster presentation 1
Title: Patient preference for tivozanib hydrochloride or sunitinib in the treatment of metastatic renal cell carcinoma (mRCC): TAURUS study
Abstract Number: 892TiP
Room: Hall XL
Presenter: Bernard Escudier, M.D.
Date & Time: Sunday, September 30, 2012 at 1:00 p.m. (CEST)
Session: Poster discussion
Title: Pharmacodynamic (PD) – Pharmacokinetic (PK) study of ficlatuzumab (F), a monoclonal antibody (MAB) directed to the hepatocyte growth factor (HGF), in patients (PTS) with advanced solid tumors who have liver metastases (METS)
Abstract Number: 443PD
Room: Hall H
Presenter: Maria Elena Elez, M.D.
Date & Time: Monday, October 1, 2012 at 1:15 p.m. (CEST)
Session: Poster discussion
Title: Detailed comparison of the safety of tivozanib versus sorafenib in patients with advanced/metastatic renal cell carcinoma (mRCC) from a Phase 3 trial
Abstract Number: 795PD
Room: Hall F2
Presenter: Tim Eisen, Ph.D., FRCP
Date & Time: Monday, October 1, 2012 at 1:15 p.m. (CEST)
Session: Poster discussion
Title: Tivozanib pharmacokinetic (PK)/pharmacodynamics (PD) analysis of blood pressure (BP) and soluble vascular endothelial growth factor receptor 2 (sVEGFR2) in patients with advanced renal cell carcinoma (RCC)
Abstract Number: 796PD
Room: Hall F2
Presenter: Dmitry Nosov, M.D., Ph.D.

About AVEO

AVEO Oncology (NASDAQ: AVEO) is a cancer therapeutics company committed to discovering, developing and commercializing targeted therapies to impact patients' lives. AVEO's proprietary Human Response Platform TM provides the company unique insights into cancer biology and is being leveraged in the discovery and clinical development of its cancer therapeutics. For more information, please visit the company's website at www.aveooncology.com.

About the AVEO/Astellas Collaboration

In February 2011, AVEO and Astellas entered into a worldwide agreement outside of Asia to develop and commercialize tivozanib for the treatment of a broad range of cancers. Tivozanib, AVEO’s lead investigational drug, is a potent, selective, long half-life inhibitor of all three vascular endothelial growth factor (VEGF) receptors that is designed to optimize VEGF blockade while minimizing off-target toxicities. Subject to regulatory approval, AVEO will lead commercialization of tivozanib in North America and Astellas will lead commercialization of tivozanib in the European Union (EU).

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,810.10 -232.80 -1.37%
S&P 500 1,949.57 -22.72 -1.15%
NASDAQ 4,426.4710 -66.9190 -1.49%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs